150 related articles for article (PubMed ID: 38516338)
1. Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results.
Ratosa I; Montero A; Ciervide R; Alvarez B; García-Aranda M; Valero J; Chen-Zhao X; Lopez M; Zucca D; Hernando O; Sánchez E; de la Casa MA; Alonso R; Fernandez-Leton P; Rubio C
Clin Transl Radiat Oncol; 2024 May; 46():100764. PubMed ID: 38516338
[TBL] [Abstract][Full Text] [Related]
2. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
Palumbo I; Mariucci C; Falcinelli L; Perrucci E; Lancellotta V; Podlesko AM; Marcantonini M; Saldi S; Bini V; Aristei C
Breast Cancer; 2019 May; 26(3):290-304. PubMed ID: 30341747
[TBL] [Abstract][Full Text] [Related]
4. Ultra-Hypofractionated vs. Moderate Fractionated Whole Breast Three Dimensional Conformal Radiotherapy during the COVID-19 Pandemic.
Ivanov O; Milovančev A; Petrović B; Prvulović Bunović N; Ličina J; Bojović M; Koprivica I; Rakin M; Marjanović M; Ivanov D; Lalić N
Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35744008
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients.
Fodor A; Brombin C; Mangili P; Tummineri R; Pasetti M; Zerbetto F; Longobardi B; Galvan AS; Deantoni CL; Dell'Oca I; Castriconi R; Esposito PG; Deli AM; Rancoita PMV; Fiorino C; Vecchio AD; Di Serio MS; Di Muzio NG
Clin Breast Cancer; 2022 Jun; 22(4):e480-e487. PubMed ID: 34955430
[TBL] [Abstract][Full Text] [Related]
6. Breast, chest wall, and nodal irradiation with prone set-up: Results of a hypofractionated trial with a median follow-up of 35 months.
Shin SM; No HS; Vega RM; Fenton-Kerimian M; Maisonet O; Hitchen C; Keith DeWyngaert J; Formenti SC
Pract Radiat Oncol; 2016; 6(4):e81-e88. PubMed ID: 26723552
[TBL] [Abstract][Full Text] [Related]
7. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.
Montero A; Ciérvide R; Cañadillas C; Álvarez B; García-Aranda M; Alonso R; López M; Chen-Zhao X; Alonso L; Valero J; Sánchez E; Hernando O; García de Acilu P; Fernandez-Letón P; Rubio C
Clin Transl Radiat Oncol; 2023 Jul; 41():100651. PubMed ID: 37388711
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
[TBL] [Abstract][Full Text] [Related]
9. Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation.
Rovea P; Fozza A; Franco P; De Colle C; Cannizzaro A; Di Dio A; De Monte F; Rosmino C; Filippi AR; Ragona R; Ricardi U
Clin Breast Cancer; 2015 Aug; 15(4):270-6. PubMed ID: 25666079
[TBL] [Abstract][Full Text] [Related]
10. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity.
Ben Amor R; Bohli M; Naimi Z; Aissaoui D; Mejri N; Yahyaoui J; Hamdoun A; Kochbati L
Strahlenther Onkol; 2023 Jan; 199(1):48-54. PubMed ID: 35943552
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated Radiation Therapy (HFRT) of Breast/Chest Wall and Regional Nodes in Locally Advanced Breast Cancer: Toxicity Profile and Survival Outcomes in Retrospective Monoistitutional Study.
De Matteis S; Facondo G; Valeriani M; Vullo G; De Sanctis V; Ascolese AM; Campanella B; Scalabrino G; Osti MF
Clin Breast Cancer; 2022 Apr; 22(3):e332-e340. PubMed ID: 34670727
[TBL] [Abstract][Full Text] [Related]
13. Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost.
Franceschini D; Fogliata A; Spoto R; Dominici L; Lo Faro L; Franzese C; Comito T; Lobefalo F; Reggiori G; Cozzi L; Sagona A; Gentile D; Scorsetti M
Radiother Oncol; 2021 Nov; 164():50-56. PubMed ID: 34537289
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
De Santis MC; Bonfantini F; Di Salvo F; Fiorentino A; Riboldi VM; Di Cosimo S; Bianchi GV; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Lozza L
Clin Breast Cancer; 2018 Jun; 18(3):e363-e371. PubMed ID: 28958838
[TBL] [Abstract][Full Text] [Related]
15. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis.
Gil GOB; de Andrade WP; Diniz PHC; Cantidio FS; Queiroz IN; Gil MLBV; Almeida CAM; Caldeira PPR; Regalin M; Silva-Filho AL
Front Oncol; 2023; 13():1202544. PubMed ID: 37388233
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
Yadav BS; Sharma SC
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):874-881. PubMed ID: 29485066
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial.
Yadav BS; Dahiya D; Gupta M; Gupta A; Oinam AS; Khare S; Irrinki S; Robert N; Sakaray YR; Nagaraj SS; Kumari R
Lancet Reg Health Southeast Asia; 2024 May; 24():100392. PubMed ID: 38550605
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary results of whole breast helical tomotherapy with simultaneous integrated boost in the adjuvant treatment of breast cancer].
Liem X; Chira C; Fourquet A; Campana F; Peurien D; Fournier-Bidoz N; Kirova YM
Cancer Radiother; 2014 Jan; 18(1):15-22. PubMed ID: 24316350
[TBL] [Abstract][Full Text] [Related]
20. Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.
Dicuonzo S; Leonardi MC; Raimondi S; Corrao G; Bagnardi V; Gerardi MA; Morra A; Zerella MA; Zaffaroni M; Pansini F; Cattani F; Luraschi R; Fodor C; Veronesi P; Orecchia R; Rojas DP; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Jul; 23(7):1415-1428. PubMed ID: 33537865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
